The use of a CQR-300/IGOB-131 combination in the management of weight loss: a double-blind placebo-controlled study - Julius E Oben, Judith L Ngondi, Claudia N Momo, Gabriel A Agbor and Caroline S Makamto Sobgui Lipids in Health and Disease 2008,7:12

Abstract:

The study was a 10 week randomized, double-blind, placebo controlled design involving 72 obese or overweight participants (45.8% male; 54.2% female; ages 21–44; mean age = 29.3). The participants were randomly divided into three equal (n=24) groups: placebo, CQR-300, and CQR-300/IGOB-131 combination. Capsules containing the placebo or active formulations were administered twice daily before meals; no major dietary changes nor exercises were suggested during the study. A total of six anthropomorphic and serological measurements (body weight, body fat, waist size; total plasma cholesterol, LDL cholesterol, fasting blood glucose level) were taken at baseline and at 4, 8 and 10 weeks.

Results:Compared to the placebo group, the two active groups showed a statistically significant difference on all six variables by week 10. The magnitude of the differences was noticeable by week 4 and continued to increase over the trial period.

Conclusion: Although the CQR-300 group showed significant reductions on all variables compared to the placebo group, the CQR-300/IGOB-131 group resulted in even larger reductions. This apparently synergistic formulation should prove helpful in the management of obesity and its related complications.

Body weight: effectiveness of treatments

Table 1

Body weight: effectiveness of treatments

 

Body weight (mean kg)

Weight change (%)

 

 

Initial

4 weeks

8 weeks

10 weeks

4 Weeks-Initial

8 Weeks-Initial

10 Weeks-Initial

 

Placebo

98.05 ± 12.30

98.76 ± 8.20

96.74 ± 10.60

95.99 ± 15.20

0.72

-1.33

-2.10

CQ

98.92 ± 10.60

95.77 ± 12.32a

91.47 ± 8.69a

90.19 ± 7.60b

-3.19

-7.53†

-8.82†

CQ-IG

99.79 ± 13.50

95.77 ± 7.40

90.91 ± 5.72b *

87.95 ± 3.17c **

-4.02†

-8.90†

-11.86†

 

ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis

Body fat: effectiveness of treatments

Table 2

Body fat: effectiveness of treatments

 

Body fat (mean %)

Fat reduction (%)

 

 

Initial

4 weeks

8 weeks

10 weeks

4 Weeks-Initial

8 Weeks-Initial

10 Weeks-Initial

 

Placebo

33.32 ± 7.60

32.37 ± 12.86

32.31 ± 10.91

32.00 ± 14.63

-2.85

-3.33

-3.97

CQ

33.07 ± 10.26

30.81 ± 5.92

29.42 ± 5.49

28.23 ± 6.12a

-6.83

-11.05†

-14.63†

CQ-IG

35.66 ± 12.27

32.41 ± 7.91

29.53 ± 5.15

28.51 ± 4.17a *

-9.11†

-17.19†

-20.06‡

 

ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis

Waist size: effectiveness of treatments

Table 3

Waist size: effectiveness of treatments

 

Waist (mean cm)

Waist Change (%)

 

 

Initial

4 weeks

8 weeks

10 weeks

4 Weeks-Initial

8 Weeks-Initial

10 Weeks-Initial

 

Placebo

102.40 ± 16.26

101.82 ± 12.21

101.76 ± 13.30

101.37 ± 16.55

-0.56

-0.63

-1.00

CQ

99.83 ± 13.38

97.10 ± 18.57

93.81 ± 10.70a

91.20 ± 7.6b

-2.73

-6.03†

-8.64†

CQ-IG

104.30 ± 23.10

98.28 ± 17.41

96.00 ± 12.20b **

82.42 ± 3.88c **

-5.77†

-7.96†

-20.98†

 

ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis

Plasma total cholesterol level: effectiveness of treatments

Table 4

Plasma total cholesterol level: effectiveness of treatments

 

Total cholesterol (mean mg/dL)

Change (%)

 

 

Initial

4 weeks

8 weeks

10 weeks

4 Weeks-Initial

8 Weeks-Initial

10 Weeks-Initial

 

Placebo

146.20 ± 38.14

140.40 ± 11.11

150.06 ± 13.20

149.47 ± 19.16

-3.965

2.64

2.23

CQ

150.34 ± 21.24

122.31 ± 15.56b

116.40 ± 17.30b

110.21 ± 9.34b

-18.64†

-22.57†

-26.69†

CQ-IG

153.21 ± 20.21

108.45 ± 18.21b **

89.48 ± 10.66b ***

85.33 ± 7.80b ***

-29.21†

-41.59†

-44.30†

 

ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis

Plasma LDL cholesterol level: effectiveness of treatment

Table 5

Plasma LDL cholesterol level: effectiveness of treatments

 

LDL cholesterol (mean mg/dL)

Change (%)

 

 

Initial

4 weeks

8 weeks

10 weeks

4 Weeks-Initial

8 Weeks-Initial

10 Weeks-Initial

 

Placebo

76.13 ± 8.02

79.47 ± 7.50

74.35 ± 9.02

73.87 ± 8.44

4.38

-2.34

-2.96

CQ

80.41 ± 8.30

66.30 ± 11.06b

63.69 ± 8.79b

64.20 ± 11.13b

-17.55†

-20.78‡

-20.16‡

CQ-IG

86.11 ± 7.82

60.30 ± 9.39b **

57.28 ± 8.36b **

44.18 ± 10.02a **

-29.96†

-33.48‡

-48.69‡

 

ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis

Fasting blood glucose levels: effectiveness of treatments

Table 6

Fasting blood glucose levels: effectiveness of treatments

 

Blood glucose (mean mg/dL)

Change (%)

 

 

Initial

4 weeks

8 weeks

10 weeks

4 Weeks-Initial

8 Weeks-Initial

10 Weeks-Initial

 

Placebo

79.43 ± 11.63

78.34 ± 10.41

76.53 ± 10.42

77.32 ± 8.90

-1.37

-3.67

-2.65

CQ

80.32 ± 8.45

71.56 ± 5.28a

70.30 ± 9.40a

68.38 ± 7.78b

-10.90†

-12.47†

-14.85†

CQ-IG

87.68 ± 6.32

68.32 ± 11.11b *

65.47 ± 8.31b *

60.11 ± 4.31b **

-22.07†

-25.32†

-31.44‡

 

ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis